Kinfo
Rocket Pharmaceuticals, Inc. logo

Rocket Pharmaceuticals, Inc.

RCKTNASDAQHealthcare·US · USD
$2.30
-0.09 (-3.77%)
Prices as of November 13, 2026 · market closed

Price

Key statistics

Valuation
Market cap252.48M USD
Enterprise value42.35M USD
Trailing P/E-1.14
Forward P/E-1.44
PEG ratio0.00
Price / sales0.00
Price / book0.78
Profitability
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on assets-30.23%
Return on equity-5.04%
Income (TTM)
Revenue0.00 USD
Gross profit0.00 USD
EBITDA-181.93M USD
Net income-16.15M USD
Diluted EPS-$0.15
Rev. growth (YoY)0.00%
Balance sheet
Total cash269.51M USD
Total debt55.04M USD
Debt / equity16.85
Current ratio7.26
Book value / share$2.93
Cash flow (TTM)
Operating cash flow-158.90M USD
Levered free cash flow106.74M USD
Shares & price
Shares outstanding109.54M
Float89.18M
Held by institutions87.94%
Beta0.00
50-day MA$2.74
200-day MA$3.40
52-week high$5.45
52-week low$2.17
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-11-12-0.41-0.43−4.88%2026-08-100.27-0.38−240.74%2026-05-07-0.43-0.42+2.33%2026-02-26-0.42-0.38+9.52%
About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. is a biotechnology company focused on developing gene therapies for rare and devastating diseases, with an emphasis on inherited cardiovascular disorders, hematology, and immunology. The company’s programs are built around advanced viral vector platforms designed to address the underlying genetic cause of serious pediatric and inherited conditions. Rocket Pharmaceuticals currently develops and advances investigational and commercial genetic medicines, including therapies for disorders such as Danon disease, BAG3-related dilated cardiomyopathy, Fanconi anemia, and severe leukocyte adhesion deficiency-I. The company is also involved in manufacturing, clinical development, and the commercialization of its gene therapy products. Headquartered in Cranbury, New Jersey, Rocket Pharmaceuticals plays a specialized role in the rare-disease market by targeting conditions with significant unmet medical need through precision genetic medicine.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Gaurav D. Shah M.D.
Employees
202
Headquarters
Cranbury, NJ, United States

Frequently asked questions about Rocket Pharmaceuticals, Inc.